CoChat

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study

Open access

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Once-weekly (OW) semaglutide was associated with clinically relevant improvements in glycaemic control and body weight versus comparators in the SUSTAIN randomised controlled trials (RCTs). SURE UK, which is one of a series of individual studies that comprise the SURE programme, evaluated the use of OW semaglutide in a real-world patient population with type 2 diabetes (T2D) in the UK. METHODS: from baseline to end of study (EOS; ~ 30 weeks, although due to the COVID-19 pandemic, visits up to week 52 were permitted). Secondary endpoints included change in body weight, waist circumference and patient-reported outcomes (PROs). Physicians were to report all episodes of documented or severe hypoglycaemia, fatal events, serious adverse drug reactions, pregnancies and adverse events (AEs) in foetuses/newborn infants; other AEs during the study period could be reported on a voluntary basis. RESULT: from baseline to EOS was - 16.3 mmol/mol [95% confidence interval (CI): - 18.22, - 14.37] (- 1.5%-points [95% CI - 1.67, - 1.31]; p < 0.0001) among the 171 enrolled patients who completed the study on treatment. Mean body weight change was - 5.8 kg (95% CI - 6.75, - 4.94; p < 0.0001). Sensitivity analyses showed similar results. Improvements were also observed in other secondary endpoints, including PROs. No new safety concerns were identified with semaglutide treatment. CONCLUSION: and body weight. These results are in line with those of the SUSTAIN RCTs and support the use of OW semaglutide in routine clinical practice in adults with T2D in the UK. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT03876015.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-021-01141-8

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Patient disposition. aPatients who initiated semaglutide treatment and attended the EOS visit; b37 (21.6%) visits were carried out by telephone due to restrictions related to the coronavirus pandemic and 34 (19.9%) EOS visits were performed outside of the 28- to 38-week visit window. EAS effective analysis set, EOS end of study, FAS full analysis set, GI gastrointestinal
Fig. 1 Patient disposition. aPatients who initiated semaglutide treatment and attended the EOS visit; b37 (21.6%) visits were carried out by telephone due to restrictions related to the coronavirus pandemic and 34 (19.9%) EOS visits were performed outside of the 28- to 38-week visit window. EAS effective analysis set, EOS end of study, FAS full analysis set, GI gastrointestinalCC BY-NC · PubMed Central
Fig. 2 Proportions of patients achieving HbA1c targets and weight-reduction responses at EOS. Data are based on the effectiveness analysis set (n = 171). n indicates the number of patients contributing to the analysis. EOS end of study, HbA1c glycated haemoglobin
Fig. 2 Proportions of patients achieving HbA1c targets and weight-reduction responses at EOS. Data are based on the effectiveness analysis set (n = 171). n indicates the number of patients contributing to the analysis. EOS end of study, HbA1c glycated haemoglobinCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 41 references

Research works printed but not linked: 1

  1. Holmes P, Catarig AM, Clark A, Erhan U, Sathyapalan T. Real-world use of once-weekly semaglutide in type 2 diabetes: results from the SURE UK study. Oral presentation at Diabetes UK (DUK) Professional Conference, 19–30 April 2021, online, Abstract A21.

Cited by

See all 42

Metadata

Authors
Holmes, P., Bell, H. E., Bozkurt, K., Catarig, A.-M., Clark, A., Machell, A., & Sathyapalan, T.
Affiliations
  • Novo Nordisk (Denmark) (DK)
  • University of Hull (GB)
Corresponding author
Holmes, Patrick
Venue
Diabetes Therapy
Published
2021-09-25
Volume
12
Issue
11
Pages
2891-2905
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W3200641447
Cited by
42
References
41
Citations by year
2026: 6 · 2025: 8 · 2024: 10 · 2023: 11 · 2022: 7
FWCI
5.24
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Repository@Hull (Worktribe) (University of Hull) (submittedVersion, cc-by-nc)
Funders
novo nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
semaglutide, type 2 diabetes, real-world evidence, glycemic control, weight loss, waist circumference, patient-reported outcomes, hypoglycemia, drug safety, GLP-1 receptor agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study. https://app.cochat.ai/papers/10.1007/s13300-021-01141-8
The paper
Holmes, P., Bell, H. E., Bozkurt, K., Catarig, A.-M., Clark, A., Machell, A., & Sathyapalan, T. (2021). Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study. Diabetes Therapy. https://doi.org/10.1007/s13300-021-01141-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.